EUVIMEDEUVIMED entdecken
Crossref

Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant Cyclophosphamide

Riley M Randolph iD, Tyler C Dunlap iD, Stephany Gonzalez Tineo iD, Ryan M Kemper iD, Jing Zhu iD, Kieran Collins iD, Yu Fei Wang iD, Pu Ouyang iD, Nichole Korpi-Steiner iD, Eric Weimer iD, Morgan E Bizzell iD, Jonathan R Ptachcinski iD und 5 weitere

The Journal of Clinical Pharmacology · 2026-10 · 66 (10)

DOI: 10.1002/jcph.70305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.09.2026. Verfasst von Riley M Randolph und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Tacrolimus, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Immunosuppressive Agents. Die Arbeit nennt 47 Literaturangaben. Gefördert von: the National Institute for General Medical Sciences, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic cell transplant (allo‐HCT) is potentially curative for many hematologic diseases but complicated by acute graft‐versus‐host disease (aGVHD). While tacrolimus remains the cornerstone of aGVHD prophylaxis, regimens are increasingly including post‐transplant cyclophosphamide (PTCy). This single‐center study evaluated a previously published tacrolimus population pharmacokinetic (popPK) model developed from allo‐HCT recipients administered standard (tacrolimus plus methotrexate) aGVHD prophylaxis for generalizability to PTCy recipients. Adult allo‐HCT recipients treated with PTCy for aGVHD prophylaxis were included. Applicability of the established popPK model to the PTCy population was based on an evaluation of simulated to observed concentration ratios, and the distribution was interpreted with respect to a clinical equivalence range (0.8 to 1.25). The model was refit using data from both the standard and PTCy cohorts to describe the PK and support extrapolation to the PTCy population. Individual PK parameters from PTCy recipients were used to simulate steady‐state concentrations (C trough, ss ) using the current institutional weight‐based dosing strategy and the proposed model‐informed precision dosing (MIPD) algorithm. The proportion of patients predicted to experience a subtherapeutic C trough, ss (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusHematopoietic Stem Cell TransplantationCyclophosphamideImmunosuppressive AgentsModels, BiologicalGraft vs Host DiseaseHumansAdultMaleFemaleMiddle AgedTransplantation, HomologousAgedYoung Adult

Stichwörter der Autor:innen

acute graft‐versus‐host diseaseallogeneic hematopoietic cell transplantmodel‐informed precision dosingpopulation pharmacokineticspost‐transplant cyclophosphamidetacrolimus

Substanzen

TacrolimusCyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
  • Metrum Research Group, Boston, MA, USA.
  • Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
  • Bone Marrow Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC, USA.
  • Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

ORCID-Profile: Riley M Randolph, Tyler C Dunlap, Stephany Gonzalez Tineo, Ryan M Kemper, Jing Zhu, Kieran Collins, Yu Fei Wang, Pu Ouyang, Nichole Korpi-Steiner, Eric Weimer, Morgan E Bizzell, Jonathan R Ptachcinski, Anson E Snow, Paul M Armistead, J Ryan Shaw, Daniel L Weiner, Daniel J Crona

Förderung

  • the National Institute for General Medical Sciences
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Randolph, R. M., Dunlap, T. C., Tineo, S. G., Kemper, R. M., Zhu, J., Collins, K., Wang, Y. F., Ouyang, P., Korpi-Steiner, N., Weimer, E., Bizzell, M. E., Ptachcinski, J. R., Snow, A. E., Armistead, P. M., Shaw, J. R., Weiner, D. L., & Crona, D. J. (2026). Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant Cyclophosphamide. The Journal of Clinical Pharmacology, 66(10). https://doi.org/10.1002/jcph.70305

Vancouver

Randolph RM, Dunlap TC, Tineo SG, Kemper RM, Zhu J, Collins K, et al. Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant Cyclophosphamide. The Journal of Clinical Pharmacology. 2026;66(10). doi:10.1002/jcph.70305

BibTeX
@article{Randolph2026,
  author = {Randolph, Riley M and Dunlap, Tyler C and Tineo, Stephany Gonzalez and Kemper, Ryan M and Zhu, Jing and Collins, Kieran and Wang, Yu Fei and Ouyang, Pu and Korpi-Steiner, Nichole and Weimer, Eric and Bizzell, Morgan E and Ptachcinski, Jonathan R and Snow, Anson E and Armistead, Paul M and Shaw, J Ryan and Weiner, Daniel L and Crona, Daniel J},
  title = {Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant Cyclophosphamide},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {10},
  doi = {10.1002/jcph.70305}
}
Kostenlos starten →